United States News All stories

Chinese camera maker Insta360 is stepping up its US drone push as regulators tighten curbs on rival manufacturers.

Singapore Exchange has rolled out crypto futures contracts aimed at institutional traders looking for regulated market access.

The US Senate Banking Committee is advancing sweeping crypto legislation to clarify rules and support domestic digital asset innovation.

Labour MPs are urging the UK government to ban crypto political donations as concerns grow over transparency and election integrity.

USANA Health Sciences (NYSE:USNA), a global leader in nutritional supplements and wellness products sold through direct selling, today announced preliminary fiscal year 2025 net sales results and its initial net sales outlook for fiscal 2026 ahead of its presentation at the 28th Annual ICR Conference.

XPENG (NASDAQ:XPEV) solidified its position as a frontrunner in the global electric vehicle race on Monday, unveiling its 2026 flagship P7+ and a suite of "Physical AI" milestones that signal a decisive shift toward autonomous mobility.

Viridien (NYSE:CCG), the advanced technology and digital data group formerly known as CGG, released a bullish preliminary 2025 update on Monday, showcasing the fruit of its multi-year "asset-light" transformation.

Evolus (NASDAQ:EOLS), a global performance beauty company dedicated to building a differentiated aesthetic portfolio, announced preliminary, unaudited net revenue results for the fourth quarter and full year ended December 31, 2025, along with updated forward-looking guidance.

Amazon Pharmacy (NASDAQ:AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers Novo Nordisk’s Wegovy® pill, the first and only FDA-approved oral GLP-1 for weight management, through many insurance plans as well as a transparent cash-pay option.

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it has entered into an exclusive global license agreement with Pfizer (NYSE:PFE) for ervogastat (formerly PF-06865571), an oral diacylglycerol acyltransferase 2 (DGAT-2) inhibitor currently in Phase 2 development, as well as rights to two additional early-stage metabolic dysfunction-associated steatohepatitis (MASH) assets.

Boston-based Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, announced preliminary, unaudited net product revenues for its flagship therapy IMCIVREE (setmelanotide) for the fourth quarter and full year ended December 31, 2025.

Beijing-based Global Mofy Metaverse Limited (NASDAQ:GMM), a technology platform specializing in AI-driven virtual content creation for the metaverse and entertainment industries, reported record financial results for its fiscal year ended September 30, 2025.

Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.

Cartesian Therapeutics (NASDAQ:RNAC) provided an update on its Descartes-08 program, a first-in-class autologous mRNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases, and outlined key 2026 priorities.

Indianapolis-based Hurco Companies (NASDAQ:HURC), a global provider of computerized machine tools and software, reported financial results for its fiscal year ended October 31, 2025.

Schrödinger (NASDAQ:SGDR) announced a strategic collaboration with Eli Lilly and Company (NYSE:LLY) on Friday to integrate Lilly’s high-powered TuneLab™ AI platform directly into Schrödinger’s flagship enterprise software, LiveDesign.

Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.

Polestar Automotive Holding UK (NASDAQ:PSNY) reported its strongest sales year to date on Friday, defying a broader slowdown in the electric vehicle sector with a 34% surge in annual retail deliveries.

The Kroger Company (NYSE:KR) completed the sale of its online health-and-wellness subsidiary, Vitacost.com, to iHerb on Friday, a move aimed at excising non-core digital assets as the grocery giant narrows its focus on its primary retail operations and high-return business lines.

Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.

Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.

Amarin Corporation (NASDAQ:AMRN) commented on recent therapeutic advances for patients with elevated triglycerides, asserting that its flagship VASCEPA/VAZKEPA (icosapent ethyl) franchise remains strongly positioned to benefit from broader category commercialization efforts.

California-based MapLight Therapeutics (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, provided an update on the progress of its two ongoing Phase 2 studies.

Lindsay Corporation (NYSE:LLN), a global heavyweight in automated irrigation systems and roadway infrastructure, announced Friday that its Board of Directors has authorized a regular quarterly cash dividend of $0.37 per share.